TITLE: Tiopronin for Cystinuria in Pediatric Patients: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

DATE: 24 January 2017

RESEARCH QUESTIONS

1. What is the clinical effectiveness of tiopronin for the prevention of kidney stone formation in pediatric patients diagnosed with cystinuria?

2. What is the cost-effectiveness of tiopronin for the prevention of kidney stone formation in pediatric patients diagnosed with cystinuria?

3. What are the evidence-based guidelines regarding the use of tiopronin in pediatric patients diagnosed with cystinuria?

KEY FINDINGS

No relevant literature was identified regarding the clinical or cost-effectiveness of tiopronin for the prevention of kidney stone formation in pediatric patients diagnosed with cystinuria. In addition, no evidence-based guidelines were identified regarding the use of tiopronin in pediatric patients diagnosed with cystinuria.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to health technology assessments, systematic reviews, meta-analyses, randomized controlled trials and economic studies. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2009 and December 18, 2016. Internet links were provided, where available.

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that the Canadian Agency for Drugs and Technologies in Health (CADTH) could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the web sites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.
SELECTION CRITERIA

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

<table>
<thead>
<tr>
<th>Table 1: Selection Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population</strong></td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
</tr>
<tr>
<td><strong>Comparator</strong></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Study Designs</strong></td>
</tr>
</tbody>
</table>

RESULTS

No relevant health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, or economic evaluations were identified regarding the clinical or cost-effectiveness of tiopronin for the prevention of kidney stone formation in pediatric patients diagnosed with cystinuria. In addition, no evidence-based guidelines were identified regarding the use of tiopronin in pediatric patients diagnosed with cystinuria.

References of potential interest are provided in the appendix.

- **Health Technology Assessments**
  No literature identified.

- **Systematic Reviews and Meta-analyses**
  No literature identified.

- **Randomized Controlled Trials**
  No literature identified.

- **Non-Randomized Studies**
  No literature identified.

- **Economic Evaluations**
  No literature identified.

- **Guidelines and Recommendations**
  No literature identified.
APPENDIX – FURTHER INFORMATION:

Non-Randomized Studies

Pediatric Case Reports


No Specific Mention of Tiopronin


Adult Case Report – Alternate Indication


Conference Abstracts

Pediatric Case Report (Alternate Indication)


Mixed or Unclear Population


Guidelines and Recommendations – Adult Population


   NGC summary available from: https://guideline.gov/summaries/summary/48229
   See: Recommendation 20

Clinical Practice Guidelines – Unspecified Methodology

Unsure if Specific Recommendations are for the Pediatric Population

   See: Figure 6

Review Articles


   PubMed: PM25383320


